相关实验视频
Updated: Jun 22, 2026

11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
在患有牛皮的患者中按需要剂量服用比梅奇祖马布:一个病例系列
Carlota Abbad-Jaime De Aragón1,2, Emilio Berna-Rico1,2, Pedro Jaén1,2
1Department of Dermatology, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
The Journal of dermatological treatment
|April 21, 2025
概括
这项研究探索了一种非标签的,根据需要的比梅奇祖马布在牛皮患者的剂量策略. 结果显示,在维持PASI90反应方面具有很高的疗效,没有观察到任何不良事件.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛皮的治疗已经取得了进展,但对非标签剂量生物疗法的研究仍然很少.
- 生物疗法对中度至重度的牛皮有显著的益处.
研究的目的:
- 为了评估非标签的疗效和安全性,根据需要对中度至重度牛皮的比梅奇祖马布剂量方案.
- 通过这种剂量策略,评估随着时间的推移保持最佳皮肤控制 (PASI90响应).
主要方法:
- 追溯28名中度至重度牛皮患者的病例系列,这些患者在64周内接受了比梅奇祖马布治疗.
- 非标签,根据需要的剂量策略,在第0周和第4周开始用两剂,随后的剂量基于维持PASI90反应.
主要成果:
- 在28名患者中,有27名患者在初始比梅奇祖马布剂量后获得了PASI90反应.
- 所有患者在整个研究期间都保持了PASI90反应,并根据需要给药.
- 在研究期间没有报告任何不良事件.
结论:
- 一个非标签的,根据需要的比梅奇祖马布剂量策略似乎有效地维持了牛皮患者的PASI90反应.
- 需要进一步的前性研究来比较这种疗法与标签上的标准剂量.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
102
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
102
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
101
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
101
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
86
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
86
Inflammatory Bowel Disease IV: Pharmacological Management
80
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
80

